The Rochester Clinical and Translational Science Award (RCTSA) Program proposes continuation of its dual goals: 1) To organize, support, and expand clinical and translational research at the University of Rochester within an academic home, the University of Rochester Clinical and Translational Science Institute (URCTSI), and 2) To integrate and collaborate with regional and national institutions to expand a National Clinical and Translational Research Network. The RCTSA Program has truly transformed the University of Rochester Medical Center (URMC), with the construction of a state-of-the-art Clinical and Translational Science Building, the integration of clinical and translational science into the shared vision for URMC research, a successful system of dynamic governance, expansion of research resources, and enthusiastic participation and leadership in the National CTSA Consortium. To continue this momentum, the UR-CTSI will carry out a number of specific aims. First, three new key functions will be implemented: Public-Private Partnerships, Tl Translation, and Comparative Effectiveness Research. Existing Key Functions will be reorganized and consolidated to provide better support of investigators by an expanded Office of Regulatory Support, a Navigator/Consultation Service, and an Incubator Program consolidating Pilot Studies, Novel Methodologies, and Translational Technologies Key Functions. The CTSI will establish and foster four centers of research excellence across the spectrum of research translation: Center for Human Experimental Therapeutics (Tl Research);Clinical Research Center (T1-3 Research);Center for Research Implementation and Translation (T2-3 research under School of Nursing sponsorship);and Center for Community Health (T2-3 research). A broad range of education, training, and career development programs will continue to meet research workforce needs. The UR-CTSI will be an active participant in the National CTSA consortium with sharing of expertise, methods, data, and curricula. The Upstate New York Translational Research Network (UNYTRN) will be expanded to support the region's biomedical research institutions. Finally, the UR-CTSI will be evaluated through the measurement of rigorous performance outcomes.

Public Health Relevance

The UR Clinical and Translational Science Institute (UR-CTSI) will be the focal point for translation of basic discoveries to human applications and clinical trials, and for evidence-based implementation of efficacious clinical practices and effective community strategies. The UR CTSI will be a model for CTSA involvement of nursing, dentistry, and other disciplines, for engagement ofthe Rochester community in all aspects of research and for collaboration with regional biomedical institutions in research translation.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Training Award (TL1)
Project #
5TL1TR000096-09
Application #
8694123
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Program Officer
Rosenblum, Daniel
Project Start
2006-09-30
Project End
2016-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
9
Fiscal Year
2014
Total Cost
$229,450
Indirect Cost
$11,070
Name
University of Rochester
Department
Public Health & Prev Medicine
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Chapman, Lesley M; Ture, Sara K; Field, David J et al. (2017) miR-451 limits CD4+ T cell proliferative responses to infection in mice. Immunol Res 65:828-840
Falsetta, M L; Foster, D C; Bonham, A D et al. (2017) A review of the available clinical therapies for vulvodynia management and new data implicating proinflammatory mediators in pain elicitation. BJOG 124:210-218
Insel, Philip S; Mattsson, Niklas; Mackin, R Scott et al. (2016) Accelerating rates of cognitive decline and imaging markers associated with ?-amyloid pathology. Neurology 86:1887-96
Sabuncu, Mert R; Ge, Tian; Holmes, Avram J et al. (2016) Morphometricity as a measure of the neuroanatomical signature of a trait. Proc Natl Acad Sci U S A 113:E5749-56
Hua, Xue; Ching, Christopher R K; Mezher, Adam et al. (2016) MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials. Neurobiol Aging 37:26-37
Podhorna, Jana; Krahnke, Tillmann; Shear, Michael et al. (2016) Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies. Alzheimers Res Ther 8:8
Szpunar, Mercedes J; Belcher, Elizabeth K; Dawes, Ryan P et al. (2016) Sympathetic innervation, norepinephrine content, and norepinephrine turnover in orthotopic and spontaneous models of breast cancer. Brain Behav Immun 53:223-233
Liu, Haochen; Zhou, Xiaoting; Jiang, Hao et al. (2016) A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer's disease. Sci Rep 6:26712
Xu, Wei; Wang, Hui-Fu; Tan, Lin et al. (2016) The impact of PICALM genetic variations on reserve capacity of posterior cingulate in AD continuum. Sci Rep 6:24480
Mormino, Elizabeth C; Sperling, Reisa A; Holmes, Avram J et al. (2016) Polygenic risk of Alzheimer disease is associated with early- and late-life processes. Neurology 87:481-8

Showing the most recent 10 out of 96 publications